Developing an Innovative and De-Risked Pipeline

Melior Pipeline


A Safe and Well Tolerated Treatment for Metabolic and Liver Diseases

A new way to treat Type II Diabetes

  • Positive clinical efficacy and remarkable safety and tolerability in a Phase 2a Type II diabetes study
  • Over 300 clinical exposures to date
  • 700 total clinical exposures expected by Q1 2019
  • Additional safety data from a Phase 2b Type II Diabetes study expected Q1 2019.

Strong potential for clinical development in NASH

  • Positive results in a comprehensive preclinical model of NASH
  • Improvement in NAS score and key measures of NASH


Addressing Unmet Needs in Parkinson’s Disease
  • Mesocarb is a highly selective, well tolerated, dopamine reuptake inhibitor with strong preclinical data in Parkinson’s Dyskinesia
  • A well characterized molecule that has been available commercially outside the United States
  • Over 40 clinical publications
  • Over one million patient-years exposure to date